Yes, seems like the age old notion of: the house always wins, too big to fail (what would be the consequences of BP's failing? Unthinkable...the economy, the FDA's sweetheart deals and control, not regulation, of pharmaceutical sector, continued government bureaucracy, corruption, status quo with no room for shake up in industry by smaller innovative newcomers), and of course, nothing succeeds like success.
Two things give one hope in our case that this could change (if ever):
1. So far, it appears BP doesn't want to give small biotechs, Anavex, a place at the table for the ultra indication...Alzheimer's. They cling to the Amyloid hypothesis come Hell or high water. And when it fails, they just find a new way to try to push it. Younger, healthier subjects need to take it longer, more money - almost makes one wonder if they aren't happy to have it fail in older diagnosed population as now they stand to gain even more? Could have been an ingenious Plan B they all contrived (seeing as they all threw in the towel pretty willingly on the trials which tanked), but that may sound too conspiratorial and may be giving them too much credit? Don't know.
Still, doesn't it seem odd that no one (BP, FDA, media) is fighting A2-73's potential in the much smaller arena of Rett Syndrome? Or even Parkinson's? Seems all the bashing we get is about the inability of A2-73's science to make a dent in Alzheimer's. It's the same science, same management, only difference is the market size.
The fact that we have these indications going for us (if/when trials commence), along with at least one BP willing to acknowledge our science to potentially contribute to a success in battling MS, reassures me that there is merit to our science and our management. So, these will have to succeed and be our cracks in the giant wall protecting BP's amyloid monopoly (which ironically holds no hope for patients - it's never really about the patients for BP, is it?).
2. The second cause for hope is the proposed changes to the government's role in the regulation of pharmaceuticals.
If these things align, our chance for recognition for AD will be greatly enhanced - although only to the point of a BP tuck in or buyout. In my opinion, that's the reality and Missling knows it and will get best deal possible when the time comes.
